Skip to main content

Table 2 Univariate and multivariate analysis of FRGS, clinical and pathologic factors with DFS of stage II/III patients in training and validation cohorts

From: Cancer-associated fibroblasts impact the clinical outcome and treatment response in colorectal cancer via immune system modulation: a comprehensive genome-wide analysis

Characteristic Training cohort (GSE39582, n = 461) Validation-1 cohort (TCGA, n = 338) Validation-2 cohort (meta-validation, n = 553)
Univariate Multivariate Univariate Multivariate Univariate Multivariate
HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value
FRGS 3.33 (1.95–5.68) < 0.001 3.19 (1.88–5.41) < 0.001 5.00 (1.58–15.85) < 0.01 5.00 (1.58–15.85) < 0.01 3.25 (1.55–6.81) < 0.01 2.99 (1.44–6.21) < 0.01
Gender 1.53 (0.89–2.62) 0.12    1.56 (0.81–2.99) 0.18    0.70 (0.42–1.16) 0.16   
Age 1.01 (0.99–1.03) 0.58    1.01 (0.98–1.04) 0.37    0.98 (0.97–1.00) 0.07   
Tumor location 1.08 (0.64–1.84) 0.78    1.09 (0.59–2.04) 0.78    0.82 (0.40–1.66) 0.58   
TNM stage 7.89 (1.11–55.91) 0.01 7.46 (1.05–52.99) 0.04 1.83 (0.76–4.41) 0.17    3.59 (1.30–9.93) < 0.01 3.39 (1.22–9.40) 0.02
MMR status 1.63 (0.70–3.82) 0.25    0.64 (0.34–1.24) 0.18    0.88 (0.38–2.04) 0.76   
CIMP status 0.95 (0.44–2.02) 0.89        0.91 (0.36–2.28) 0.84   
CIN status 1.69 (0.75–3.81) 0.2           
TP53 mutation 1.39 (0.78–2.48) 0.27        2.74 (0.60–12.43) 0.17   
KRAS mutation 1.44 (0.86–2.40) 0.16    1.02 (0.23–4.60) 0.98    1.23 (0.53–2.87) 0.63   
BRAF mutation 1.42 (0.57–3.58) 0.45    0.00 (0.00–Inf) 0.72    2.04 (0.81–5.10) 0.12